AGN

Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD

Retrieved on: 
Thursday, November 30, 2023
NAFLD, Risk, NASH, Fatty liver disease, AGN, Type, Inflammation, Standard of care, Patent, Insulin resistance, Laboratory, Obesity, Patient, Telmisartan, Steatosis, Fibrosis, UUO, CKD, Pharmaceutical industry

The invention claims treating lobular inflammation and nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH) and NASH-derived hepatocellular carcinoma, with Repirinast.

Key Points: 
  • The invention claims treating lobular inflammation and nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH) and NASH-derived hepatocellular carcinoma, with Repirinast.
  • The base claims of the patent will be valid through 2038, excluding any patent term adjustments or extensions which may provide additional protection.
  • The Company was recently issued patents for Repirinast in NASH from the U.S. and Japan, and has also filed corresponding patent applications in Canada and Europe.
  • “We are pleased to receive this notice of intent to grant from the Chinese Patent Office,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals.

Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

Retrieved on: 
Wednesday, November 22, 2023
Patient, Food, Ifenprodil, U.S. FDA, Drug discovery, FDA, Idiopathic pulmonary fibrosis, AGN, IPF, Brain, USD, LOI, Chronic cough, NMDA, Pharmaceutical industry

Seyltx plans to conduct an Ifenprodil Phase 2b chronic cough study as soon as possible.

Key Points: 
  • Seyltx plans to conduct an Ifenprodil Phase 2b chronic cough study as soon as possible.
  • As stated in the LOI, Algernon’s clinical management team will be available to provide support, oversight and management of the study.
  • Ifenprodil is Algernon’s lead research program and represents a novel first-in-class potential treatment for chronic cough.
  • “We are very pleased to have signed this LOI with Seyltx,” said Christopher J. Moreau, Algernon’s Chief Executive Officer.

Algernon Pharmaceuticals Receives Japanese Patent Notice of Allowance for Treatment of NASH with Repirinast

Retrieved on: 
Wednesday, November 8, 2023
Standard of care, Patent, Obesity, Laboratory, Fibrosis, Inflammation, CSE, Fatty liver disease, Type, Steatosis, NASH, Risk, UUO, Telmisartan, AGN, NAFLD, CKD, Insulin resistance, Patient, Pharmaceutical industry, Repirinast

VANCOUVER, British Columbia, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has received a Notice of Allowance from the Japanese Patent Office for patent application No.

Key Points: 
  • VANCOUVER, British Columbia, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has received a Notice of Allowance from the Japanese Patent Office for patent application No.
  • The invention claims treating nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH) and NASH-derived hepatocellular carcinoma, with Repirinast.
  • The base claims of the patent will be valid through 2038, excluding any patent term adjustments or extensions which may provide additional protection.
  • The Company was recently issued a patent from the US patent office for Repirinast in NASH and has also filed corresponding patent applications in Canada, Europe, and China.

Redomiciliation to Bermuda completed

Retrieved on: 
Saturday, September 30, 2023
Bermuda Monetary Authority, ISIN, AGN, AEG, EGM, Bermuda, Documentation, NYSE, Euronext Amsterdam, Airline, The Hague, Aegon

The Hague, September 30, 2023 - Aegon’s Extraordinary General Meeting of shareholders (EGM) today approved the cross-border conversion into a Bermuda Limited company.

Key Points: 
  • The Hague, September 30, 2023 - Aegon’s Extraordinary General Meeting of shareholders (EGM) today approved the cross-border conversion into a Bermuda Limited company.
  • After the completion of the EGM, the change of Aegon’s legal seat to Bermuda has been effectuated, as a result of which the company became a Bermuda entity: Aegon Ltd. As of October 1, 2023, the Bermuda Monetary Authority will be Aegon’s group supervisor.
  • Aegon shares will continue to be listed on Euronext Amsterdam (AGN) and NYSE (AEG).
  • The identifiers (such as the ISIN) of the Aegon shares will change:
    the Aegon Ltd. common shares will have the ISIN BMG0112X1056; and
    More information on the redomiciliation, as well as the documentation relating to it, can be found here .

Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH

Retrieved on: 
Wednesday, September 6, 2023
Telmisartan, Patent, Steatosis, Insulin resistance, Laboratory, Obesity, CSE, NASH, AGN, Inflammation, UUO, Fibrosis, Algernon, Standard of care, Patient, Risk, Fatty liver disease, Type, NAFLD, CKD, Pharmaceutical industry, Repirinast

11744808, for its lead chronic kidney Disease (CKD) program drug NP-251 (Repirinast), entitled “Compositions and Methods for Treating Non-Alcoholic Steatohepatitis.”

Key Points: 
  • 11744808, for its lead chronic kidney Disease (CKD) program drug NP-251 (Repirinast), entitled “Compositions and Methods for Treating Non-Alcoholic Steatohepatitis.”
    The invention claims treating non-alcohol fatty liver disease (NAFLD), including non-alcoholic steatohepatitis (NASH) and NASH-derived hepatocellular carcinoma, with Repirinast.
  • The base claims of the patent will be valid through 2039, excluding any patent term adjustments or extensions which may provide additional protection.
  • The Company has also filed corresponding patent applications in Canada, Europe, China and Japan.
  • “This is the first patent received from the USPTO by Algernon for one of its drugs being investigated under its innovative drug repurposing program and is further validation of our intellectual property strategy,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals.

Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study

Retrieved on: 
Tuesday, August 8, 2023
Molecule, Neuron, Rat, DMT, CSE, DMT: The Spirit Molecule, Depression, Neuroplasticity, Stroke, Clinical trial, Penile spines, AGN, Pharmacokinetics, Brain, Biomarker, Signal transduction, Plasma, Ethics, Patient, Growth, Diagnosis, BDNF, Death, Imperial College London, CHDR, Safety, Pharmaceutical industry

VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro), has completed a feasibility study and has finalized its clinical trial design for a 40 patient Phase 2 DMT Stroke study.

Key Points: 
  • VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro), has completed a feasibility study and has finalized its clinical trial design for a 40 patient Phase 2 DMT Stroke study.
  • The Phase 2 human stroke trial will study an intravenous sub-psychedelic dose of DMT in patients who are hospitalized after having suffered an acute ischemic stroke.
  • Algernon consultant Dr. Rick Strassman, DMT research pioneer and author of the books DMT: The Spirit Molecule and The Psychedelic Handbook commented: “I am encouraged by the results of Algernon’s Phase 1 study in which a prolonged infusion of DMT achieved the desired pharmacokinetics.
  • “We are investigating DMT as a potential new therapeutic treatment that could have a positive impact on ischemic stroke patients worldwide.”

LeaseCrunch Announces Upcoming Webinar “Preparing for the Next Phase: Ensuring Long-Term Lease Accounting Success”

Retrieved on: 
Monday, July 31, 2023
GASB, ASC, Success, AGN, LEA Global, CDT, Accounting, Property management, Airline

MILWAUKEE, Wis., July 31, 2023 (GLOBE NEWSWIRE) -- LeaseCrunch LLC , a leading accounting software company, today announced its upcoming webinar “Preparing for the Next Phase: Ensuring Long-Term Lease Accounting Success.” This webinar, taking place on August 23 at 1:00 p.m. CDT, will explore the crucial steps to prepare for the next chapter of ASC 842 lease accounting implementation.

Key Points: 
  • MILWAUKEE, Wis., July 31, 2023 (GLOBE NEWSWIRE) -- LeaseCrunch LLC , a leading accounting software company, today announced its upcoming webinar “Preparing for the Next Phase: Ensuring Long-Term Lease Accounting Success.” This webinar, taking place on August 23 at 1:00 p.m. CDT, will explore the crucial steps to prepare for the next chapter of ASC 842 lease accounting implementation.
  • Led by Jess Vento, senior director of accounting at LeaseCrunch, participants will gain valuable insights and strategies to ensure extended success in lease accounting.
  • “We are looking forward to bringing this webinar to the public,” states Vento.
  • “At LeaseCrunch, we are committed to providing our customers with the tools and insights to ensure long-term lease accounting success.

Algernon Pharmaceuticals Announces Private Placement and Issuance of Shares in Connection with Financial Advisory Agreement

Retrieved on: 
Friday, July 14, 2023
Acceleration, Engagement letter, Indian stock exchange, CSE, Legislation, CDN, AGN, Expiry Date (miniseries), Warrant, Expiration date, Exercise, Letter, News, Regulation, Security (finance), Maxim

Each Unit will consist of one Class A common share in the capital of the Company (a “Common Share”) and one Common Share purchase warrant (a “Warrant”).

Key Points: 
  • Each Unit will consist of one Class A common share in the capital of the Company (a “Common Share”) and one Common Share purchase warrant (a “Warrant”).
  • The Company will use the proceeds of the private placement for working capital purposes.
  • In connection with entering into the Engagement Letter, the Company may be obligated to issue up to an additional 200,000 Common Shares to Maxim in certain circumstances.
  • The Company may also be obligated to pay Maxim a success fee upon the consummation of a successful transaction.

Algernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Program

Retrieved on: 
Tuesday, June 27, 2023
Manchester University NHS Foundation Trust, GSK, Montefiore Medical Center, CSE, University, Critical Care Medicine (journal), RCC, Drug discovery, AGN, NMDA, Brain, Merck & Co., USD, Chronic cough, GSK plc, Acquisition, Patient, Division, Respiratory Medicine, Internal medicine, NHS foundation trust, University of Manchester, Merck, IPF, Regulation of tobacco by the U.S. Food and Drug Administration, P2X3, Idiopathic pulmonary fibrosis, Food, Ifenprodil, Pharmaceutical industry, Bellús

Ifenprodil represents a novel first-in-class potential treatment for chronic cough and is thought to interfere with central signaling in the brain, suppressing the urge to cough.

Key Points: 
  • Ifenprodil represents a novel first-in-class potential treatment for chronic cough and is thought to interfere with central signaling in the brain, suppressing the urge to cough.
  • Patients with IPF are usually excluded from trials in refractory chronic cough (“RCC”), and cough in this population is regarded as extremely difficult to treat.
  • Algernon previously announced on January 14, 2022, that it had received positive feedback from the U.S. Food and Drug Administration at its pre-Investigational New Drug (pre-IND) meeting for its investigation of Ifenprodil solely for the treatment of chronic cough.
  • She runs a multi-disciplinary research team whose focus is on understanding mechanisms underlying pathological cough and a regional clinical service seeing patients with refractory chronic cough.

COP28 must deliver for the most vulnerable, President-Designate tells UN climate change conference

Retrieved on: 
Sunday, June 11, 2023
SIDS, Food, COP28, Solidarity, Global stocktake, 2019 UN Climate Action Summit, G77, Negotiation, AGN, Human, LDC, Carbon, Paris Agreement, Wind, COP, Biodiversity, Indigenous peoples, Least developed countries, Climate change, Capacity building, Fossil, Nature, African Group, COP27, Party, Global North and Global South, Growth, Health, Delegation, Environment, Kunst- und Ausstellungshalle der Bundesrepublik Deutschland, Conference, SB, Tourism, Agriculture, Renewable energy, UNFCCC, Expo

And we will give the space and enabling environment to discuss, debate and align on every mandate across every climate pillar."

Key Points: 
  • And we will give the space and enabling environment to discuss, debate and align on every mandate across every climate pillar."
  • "Everyone is affected and the most vulnerable communities who have done the least to cause climate change, are the most affected.
  • He introduced COP28's Youth Climate Champion, Shamma Al Mazrui, who stressed the importance of including youth in all conversations around climate change.
  • As mandated by the Paris Climate Agreement, COP28 UAE will deliver the first ever Global Stocktake – a comprehensive evaluation of progress against climate goals.